Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WTYX10002
- Development stage
- Unknown
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
WTYX10002 (also known as VZV-7D or v7D) is a novel live-attenuated varicella vaccine being developed by Sino-Innovax Biotech (a subsidiary of Wantai BioPharm) in collaboration with Xiamen University. Unlike traditional varicella vaccines that utilize the Oka strain (vOka), WTYX10002 is constructed using reverse genetics to delete the ORF7 gene, which is essential for skin and neural tropism. This genetic modification prevents the vaccine strain from causing skin lesions (varicella-like rash) or establishing latent infection in the dorsal root ganglia, thereby eliminating the risk of vaccine-induced varicella and subsequent reactivation as herpes zoster (shingles). WTYX10002 is currently in Phase III clinical development for the prevention of varicella (chickenpox) caused by varicella-zoster virus infection in children.
- Other names
- Novel Varicella Vaccine
Beyond the preview
Go deeper on WTYX10002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WTYX10002.